Sold as Lymphazurin. Every FDA application for this active ingredient: 1 branded and 8 generic.
As of Nov 16, 2026, FDA lists 9 applications for Isosulfan Blue (sold as Lymphazurin), first approved Jul 29, 1981, with 0 new uses approved and 0 published complete response letters.
| Jul 29, 1981 | LymphazurinNDA 18310 · New molecular entity | Covidien | 9 | Discontinued |
| Jul 20, 2010 | Isosulfan BlueANDA 90874 | Mylan Institutional | 1 | Marketed |
| Feb 2, 2016 | Isosulfan BlueANDA 206831 | Eugia Pharma | 0 | Marketed |
| Jan 16, 2019 | Isosulfan BlueANDA 210714 | Saba Ilay Sanayi | 0 | Marketed |
| Jul 12, 2019 | Isosulfan BlueANDA 210558 | Somerset Theraps LLC | 0 | Marketed |
| Nov 3, 2021 | Isosulfan BlueANDA 213130 | Meitheal | 0 | Marketed |
| Sep 8, 2022 | Isosulfan BlueANDA 211869 | Fresenius Kabi USA | 0 | Discontinued |
| Sep 16, 2022 | Isosulfan BlueANDA 216090 | Msn | 0 | Marketed |
| May 17, 2023 | Isosulfan BlueANDA 210294 | Am Regent | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA